Description

The data presented in the Vaccine Tracker are submitted by European Union/European Economic Area (EU/EEA) countries to ECDC through The European Surveillance System (TESSy) once every two weeks on Tuesdays. EU/EEA countries report aggregated data on the number of vaccine doses distributed by manufacturers to the country, the number of first, second, additional and unspecified doses administered to adults (18+), adolescent and children (<18) overall, by age groups and in specific target groups, such as healthcare workers (HCWs) and in residents in long-term care facilities (LTCFs). Doses are also reported by vaccine product.

The downloadable data files contain the data on the COVID-19 vaccine rollout mentioned above and each row contains the corresponding data for a certain week and country. The files are updated once every two weeks on Thursdays. Data are subject to retrospective corrections; corrected datasets are released as soon as processing of updated national data has been completed. You may use the data in line with ECDC’s copyright policy.

Data dictionary

<table>
<thead>
<tr>
<th>Variable</th>
<th>Definition</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>YearWeekISO</td>
<td>Date when the vaccine was received/administered. Only weeks are allowed (e.g. “2021-W01”).</td>
<td>yyyy-Www</td>
</tr>
<tr>
<td>ReportingCountry</td>
<td>ISO 3166-1-alpha-2</td>
<td>two-letter code</td>
</tr>
<tr>
<td>Denominator</td>
<td>Population denominators for target groups (total population and age-specific population obtained from Eurostat/UN). Denominators reported by countries for TargetGroup = “HCW” and TargetGroup = “LTCF”.</td>
<td>Numeric</td>
</tr>
<tr>
<td>NumberDosesReceived</td>
<td>Number of vaccine doses distributed by the manufacturers to the country during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>NumberDosesExported</td>
<td>Number of vaccine doses donated or sold by the country during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>FirstDose</td>
<td>Number of first dose vaccine administered to individuals during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>FirstDoseRefused</td>
<td>Number of individuals refusing the first vaccine dose.</td>
<td>Numeric</td>
</tr>
<tr>
<td>SecondDose</td>
<td>Number of second dose vaccine administered to individuals during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>DoseAdditional1</td>
<td>Number of first additional vaccine doses administered after a complete standard primary course to individuals during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>DoseAdditional2</td>
<td>Number of second additional vaccine doses administered after a complete standard primary course to individuals during the reporting week.</td>
<td>Numeric</td>
</tr>
<tr>
<td>UnknownDose</td>
<td>Number of doses administered during the reporting week where the type of dose was not specified (i.e. it is not known whether it was a first or second dose).</td>
<td>Numeric</td>
</tr>
<tr>
<td>Region</td>
<td>As a minimum data should be reported at national level (Region = country code).</td>
<td>Country/NUTS1 or 2/GAUL1/Country specific</td>
</tr>
</tbody>
</table>
| TargetGroup | Target group for vaccination. | ALL = Overall adults (18+)
Age<18 = Overall adolescents and children
HCW = Healthcare workers
LTCF = Residents in long term care facilities
Age0_4 = 0-4 years old
Age5_9 = 5-9 years old
Age10_14 = 10-14 years old
Age15_17 = 15-17 years old
Age18_24 = 18-24 years old
Age25_49 = 25-49 years old
Age50_59 = 50-59 years old
Age60_69 = 60-69 years old
Age70_79 = 70-79 years old
Age80+ = 80 years and over
AgeUnk = Unknown age 1_Age<60 = adults below 60 years of age 1_Age60+ = adults 60 years and over |
| Vaccine | Name of vaccine. Additional vaccines will be added on approval or as requested. | AZ = Vaxzevria – AstraZeneca
BECNBG (previously CN) = Inactivated – Beijing CNBG
BHACOV = Covaxin – Bharat
CHU = Chumakov - Covi-Vac
COM = Comirnaty – Pfizer/BioNTech
CVAC = Curevac-CVnCOV
JANSS = Ad26.COV 2.5 – Janssen
HAYATVAC = Hayat VAC
MOD = mRNA-1273 – Moderna
NVX = Novavax – Covovax
NVXD = Novavax – Nuvaxovid
QAZVAQ = QazCovid-In
SGSK = Sanofi GSK - Subunit
SIIICOV = Covishield – SII
SIN = CoronaVac – Sinovac
SPU = Sputnik V – Gamaleya
SPUL = Gamaleya - Sputnik-Light |
Definitions

- **Healthcare workers (HCW):** refer to those who work in healthcare settings who may come into contact with patients, including clinical administration staff, and home care staff.

- **Doses of vaccines:** refers to the total number of vaccine doses, considering that an additional dose may be obtained from each vial (e.g. six doses for Pfizer BioNTech® Comirnaty).

- **Number of doses distributed** refers to the doses distributed by the manufacturers to the country.

- **Number of doses administered** refers to any individual receiving any dose of the vaccine.

- **Additional dose and boosters** refer to doses administered after a complete primary course, being them administered respectively as an extension of the primary course (e.g. in moderately to severely immunocompromised individuals) or as boosters in individuals who already received a standard primary course (e.g. see footnote with WHO definitions¹).

- **Weekly data** refer to:
  - Week of vaccine distribution by the manufacturers to the country
  - Week of vaccine dose administration to individuals receiving any of the first, second, additional or unspecified dose

  - **Booster doses** are administered to a vaccinated population that has completed a primary vaccination series (currently one or two doses of COVID-19 vaccine depending on the product) when, with time, the immunity and clinical protection has fallen below a rate deemed sufficient in that population. The objective of a booster dose is to restore vaccine effectiveness from that deemed no longer sufficient.
  - **Additional doses** of a vaccine may be needed as part of an extended primary series for target populations where the immune response rate following the standard primary series is deemed insufficient. The objective of an additional dose in the primary series is to optimize or enhance the immune response to establish a sufficient level of effectiveness against disease. In particular, immunocompromised individuals often fail to mount a protective immune response after a standard primary series, but also older adults may respond poorly to a standard primary series.